December 2012 – Pfizer agrees to pay $43 million to settle allegations that it improperly marketed Lyrica and other medications for “off-label” uses not approved by the FDA.
December 2012 – Pfizer agrees to pay $43 million to settle allegations that it improperly marketed Lyrica and other medications for “off-label” uses not approved by the FDA.